Kornimate/medical-research-clean huggingface dataset:
endodontic medications for irreversible pulpitis: articaine or eugenol?

Conditions: Pulpitides; Endodontic Inflammation; Toothaches; Operative Dentistry

Summary: the objective of the study is to determine which of the two commonly used endodontic medications (eugenol vs articaine) is most effective in controlling postoperative pain in irreversible pulpitis of the mature permanent tooth in adults. to do so, an assessment of the pain felt by patients will be carried out a few days apart. the supposed results are that the medications are equivalent in terms of effectiveness on the pain, but could then present different economic arguments

in irreversible pulpitis of the mature permanent tooth, the enrolled patients receive endodontic medications (eugenol or articaine) in order to determine which one is the more efficient to control the pain. these patients would have received the same medication without this study. that's why this is an obsevationnal study.

Eligibility criteria:
inclusion criteria: * adult patient, major, affiliated to a social health insurance scheme * patient having agreed to participate in the study * urgent consultant patient for irreversible pulpitis * patient understanding french exclusion criteria: * refusal of the patient to participate in the study * impossibility of performing the surgical procedure * impossibility to give the subject information enlightened (difficulty of understanding ...) * subject under the protection of justice, or under guardianship * general contraindication to endodontic treatment in 2 sessions (high risk of infectious endocarditis, for example) * chronic intake of analgesic drugs
westlake precision birth cohort

Conditions: Diabetes, Gestational; Pregnancy in Diabetics; Intrauterine Hyperglycemia

Summary: the westlake precision birth cohort (webirth) is a prospective cohort study among women with hyperglycemia during pregnancy and their offspring living in hangzhou, china. the primary aim of this cohort is to characterize the continuous blood glucose response to dietary intake and physical activity among pregnant women with gestational diabetes mellitus (gdm) over 2 weeks, and to facilitate the development of personalized nutritional/lifestyle recommendation among these patients. another aim of webirth is to investigate the association of dietary intake and physical activity together with continuous glucose change during pregnancy on the adverse birth outcomes including preterm birth, macrosomia and large-for-gestational-age birth. the secondary aim is to investigate the prospective associations of diet, physical activity and continuous glucose change over 2 weeks among the participants with long-term metabolic health of these women and their offspring.

in china, an alarming increase in the prevalence of gdm has been observed in the past decade. gdm is of concern because it is associated with several maternal and fetal medical disorders. lifestyle changes such as diet and physical activity modifications are key for the prevention and treatment of gdm. however, the associations between dietary intake and physical activity and health outcomes for gdm women and their children remain unclear due to subjective measurements of diet and physical activity. recently, the development of objective measurements such as food image identification and wearable activity trackers give an opportunity to gain more precise insight into these associations. in addition, for the same food and physical activity exposures, gdm women may have different blood glucose responses, but the nature of variation is currently poorly characterized. therefore, the present webirth design incorporates three unique components, 1) objective measurement of physical activity during pregnancy using accelerometer; 2) measurement of dietary intake using both the food frequency questionnaire and dietary records; 3) measurement of blood glucose levels over 2 weeks using continuous glucose monitors, with three standardized test meals during the 2 weeks. we will then follow up these women participants during and after this pregnancy, and also follow up their offspring.

Eligibility criteria:
inclusion criteria: * women aged 18 years or older * women with gdm at 24-28 weeks of gestation * women intended to deliver at hangzhou women's hospital * women intended to remain in hangzhou with their child for ≥4 years exclusion criteria: ● women with cancer and other serious medical disorders

Keywords: precision nutrition host and microbiome birth outcomes
outcome of arthroscopic repair of chronic rotator cuff tears between 2005-2008

Conditions: Rotator Cuff Tear

Summary: arthroscopic repair has become the preferable surgical technique to treat rotator cuff tears in the last decade. many researches demonstrate equal and even superior outcome with this surgical technique, while others show opposite results. the aim of this study is to estimate the anatomic and functional results of the arthroscopic repair among the patients of the orthopedic department at the soroka university medical center, in order to check the investigators hypothesis that indeed - the arthroscopic repair of the rotator cuff is the better surgical technique. methods: study population - 80 patients who had had an arthroscopic repair of the rotator cuff between the years 2005-2008 at the sumc. inclusion criteria: age over 18 years. arthroscopic rotator cuff repair. date of operation not before 2005. study design: 1. data base collection. 2. inviting the patients for physical examination + ultrasound examination of the operated shoulder + filling out questionnaires (sf36, constant score) 3. statistical analysis 4. publication


Eligibility criteria:
inclusion criteria: * age over 18 years * arthroscopic repair of chronic rotator cuff tear * operation done after january 2005

Keywords: arthroscopic repair rotator cuff tears shoulder chronic tear of rotator cuff
efficacy study of minoxidil lotion versus combined minoxidil and finasteride lotion to treat male pattern hair loss

Conditions: Androgenetic Alopecia

Summary: the purpose of this study is to compare the efficacy of 3% minoxidil lotion and 3% minoxidil with 0.1% finasteride lotion for 6 months in male pattern hair loss.


Eligibility criteria:
inclusion criteria: * male, age 18-15 years * androgenetic alopecia grade 3v to 5 ( norwood-hamilton classification) exclusion criteria: * use minoxidil in 6 months * use finasteride in 12 months * use ketoconazole, tar, selenium shampoo, topical tretinoin, topical steroid in 2 weeks * seborrheic dermatitis or psoriasis on scalp * history of allergy to minoxidil, finasteride

Keywords: minoxidil finasteride topical lotion male pattern hair loss androgenetic alopecia
prevalence of toxoplasma gondii and toxocara canis among patients with uveitis

Conditions: Uveitis

Summary: investigate the prevalence of toxoplasma gondii and toxocara canis in uveitis * serum antibody to t. gondii and t. canis * pcr with peripheral blood for t. gondii and t. canis * pcr with aqueous humor for t. gondii and t. canis * clinical manifestation of patient with uveitis

consecutive patients with uveitis are enrolled in nune eye hospital. serum elisa * igm,igg antibody to toxoplasma gondii * igg antibody to toxocara canis pcr * pcr with serum and aqueous humor to toxoplasma gondii * pcr with serum and aqueous humor to toxocara canis clinical characteristics * visual acuity * intraocular pressure (iop) * location and degree of inflammation * other fundus findings were recorded questionnaire * environment, occupation * pet ownership, exposure to animal * history of eating raw liver of animal, raw beef or any other raw flesh of animal.

Eligibility criteria:
inclusion criteria: * patients with uveitis exclusion criteria: * patients with history of major ophthalmic surgery within 6 months * antiviral, antifungal or antiparasitic therapy within 6 months

Keywords: toxoplasma gondii toxocara canis
agonist and antagonist muscle activations in the lower limbs during walking after central nervous system injury

Conditions: Stroke; Walking, Difficulty; Spasticity/Paresis

Summary: the retrospective study investigates the part of responsibility of neuromuscular disorders associated with chronic hemiparesis in walking impairment.

after injury to the central nervous system, walking disorders are associated with complex neuromuscular mechanisms that alter the direction and intensity of the descending control, reflex reactions to kinematic changes and the mechanical components of soft tissues. the dissociated analysis of these mechanisms and their interactions during multi-segmental movements and especially during walking is poorly described. however, a quantified assessment of the responsibility of each of the neuromuscular mechanisms in the functional disorder would guide the choice of treatments. 3d gait laboratories provide kinematic data from synchronized walking to surface electromyograms as part of additional assessments to assist in the follow-up of patients with chronic hemiparesis. retrospective analysis of these data would help to better characterize muscular activation disorders and passive resistance to movement during walking in this population.

Eligibility criteria:
inclusion criteria: * adult * person who performed tridimensional gait analysis in laboratory * person who had a stroke at least 6 months before the gait analysis exclusion criteria: * any other neurological pathology or gait disorders * botulinum toxin injection in the last 3 months before the gait analysis
a master protocol study (ly900038) of multiple intervention-specific-appendices (isas) in adult participants with obesity or overweight

Conditions: Obesity; Overweight

Summary: the purpose of this phase-2 chronic weight management master protocol (cwmm) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (isas). the cwmm establishes entry criteria for newly enrolled participants across the master and the isas. the isas may start independently of other isas as interventions become available for clinical testing. the results for the cwmm screening record will be reported when all the isa's complete.


Eligibility criteria:
inclusion criteria: * have a body mass index (bmi) * ≥30 kilogram/square meter (kg/m²), or * ≥27 kg/m² and \<30 kg/m²), or with at least 1 weight-releated comorbidity * have had a stable body weight for the 3 months prior to randomization (\<5%) body weight gain and/or loss. exclusion criteria: * have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * have poorly controlled hypertension. * have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * have any of the following cardiovascular conditions within 3 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure. * have a history of symptomatic gallbladder disease within the past 2 years. * have a lifetime history of suicide attempts.
correlation of berg balance scale, time up and go and dynamic gait index scale in elderly

Conditions: Old Age; Debility

Summary: this study will find a correlation between berg balance scale, time up and go and dynamic gait index scale in community dwelling ambulatory elderly. it will be comparative cross sectional survey that will be evaluate which scale is best one for quick screening of elderly. this study will be completed within the time duration of 6 month. convenient sampling technique will be used to collect the data. 125 sample size will be taken, in this study to find the correlation between berg balance scales. time up and go and dynamic gait index scale in community dwelling ambulatory elderly. in this study all subjects perform mini-mental state examination test to meet the inclusion criteria of the study it will be above than 25 than all subjects perform berg balance test, time up and go test and dynamic gait index test then interpret their values to find the best one scale for screening of elderly. . in this study subjects included will be living independently in the community and also those who walk without any aid. those subjects who are diagnosed with neuromuscular condition, cardiorespiratory condition, cognitive impairment and having uncorrected auditory and visual deficit will be excluded from this study. in this study we will check the static, proactive part of the dynamic balance, their gait impairments and also the risk of fall of elder population. pearson correlation data will be analyzed on spss 25.


Eligibility criteria:
inclusion criteria: 65 or above 65 years old. both male and females. living independently in the community. walking without any aid. minimental state examination score more than 25 exclusion criteria: diagnosed neuromuscular condition. diagnosed cardiorespiratory conditions. diagnosed cognitive impairment. uncorrected visual and auditory deficit
corpath® grx neuro study

Conditions: Intracranial Aneurysm; Subarachnoid Hemorrhage; Headache

Summary: the primary objective of this study is to evaluate the effectiveness and safety of robotic-assisted endovascular embolization procedures compared to objective performance criteria for traditional, manual operation based on the scientific literature.

this is a prospective, single-arm, international, multi- center, non-inferiority study to evaluate the effectiveness and safety of the corpath grx system for endovascular cerebral aneurysm embolization compared to historical controls. subject selection requires a clinical indication for endovascular coil and/or stent-assist coiling embolization of cerebral aneurysms.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. at least one cerebral aneurysm (unruptured) with indication for endovascular treatment; dome to neck ratio \>1.5 or aneurysm neck width \>4.0 mm. 3. the investigator deems the procedure appropriate for both manual or robotic-assisted endovascular treatment. 4. the conscious subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. exclusion criteria: 1. failure / unwillingness of the subject to provide informed consent, unless the ec has waived informed consent. 2. the investigator determines that the subject or the neurovascular anatomy is not suitable for robotic-assisted endovascular treatment. 3. women who are pregnant. 4. persons under guardianship or curatorship.
a clinical study to evaluate cyclopofol injection for the prevention of postoperative nausea and vomiting

Conditions: Nausea and Vomiting

Summary: this study uses cyclopropofol as a positive control and adopts a large sample, multicenter, randomized, single-blind, positive parallel control test design to explore the clinical application value of cyclopropofol in preventing postoperative nausea and vomiting.

before the end of the anesthesia maintenance period/operation, it was divided into groups a, b and c according to different drug regimens. the subjects were randomly assigned to one of them in a 1:1:1 ratio to receive cyclopophenol or sevoflurane anesthesia. each group of subjects should be roughly consistent according to the proportion of each number of po . after screening the object, the researchers of each testing center are confirmed by the researchers of the center, log in to the random system, fill in the screening information, obtain the random number information, and distribute the corresponding research drugs according to the random number. the number of random shelters is generated through sas software, which is used as a centralized random grouping system to import the total number of drugs. this study sets up evaluation researchers and drug management researchers. the whole experimental process turned a blind eye to not only the subjects, but also the evaluators. this study has set up evaluation investigators and administrative investigators. administrative researchers are only involved in the random grouping, dispensing and delivery process. other processes, including the subject's informed consent, screening, efficacy indicators and safety evaluation, and planned visits, are completed by the evaluation investigators.

Eligibility criteria:
inclusion criteria: 1. at least 2 of the 4 induced risk factors of ponv (risk factors are: history of ponv or motion sickness, habitual non-smoking, women, receiving opioid analgesia). 2. for patients with an estimated duration of anesthesia ≥1h and ≤3h (non-emergency, non-cardiothoracic surgery and non-intracranial surgery), laparoscopic surgery, gastrointestinal surgery, obstetrics and gynecology surgery, tympanoplasty, tonstonectomy, etc., are preferred. the duration of hand anesthesia was defined as the period from the beginning of anesthesia induction to the end of anesthesia maintenance 3. male or female, age ≥ 18 years old, asa-ps score i to iii. exclusion criteria: 1. there is a history of vestibular nerve disorder or dizziness or nausea and vomiting 24 hours before the operation; or receiving conventional antiemetic treatment. 2. the subjects who need to maintain ventilation after surgery or need to place the nasogastric tube in place for a period of time. 3. the subject who the researcher believes that there are any other factors that are not suitable to participate in the research.

Keywords: cyclophenol heptaflurane
remission in rheumatoid arthritis in the asian-pacific region

Conditions: Rheumatoid Arthritis

Summary: this study is the multi-center, open and cross-sectional study of ra remission in asia pacific region. the objectives is to explore remission rate of ra patients in different countries in the asian-pacific area using different criteria of remission (das28, cdai, sdai, acr/eula remission criteria, rapid3 and clin28) and investigate the associated factors of remission in ra patients.


Eligibility criteria:
inclusion criteria: * ra patients fulfilled the american college of rheumatology 1987 criteria or the 2010 acr/eular classification criteria. * patients aged \> 18 years. exclusion criteria: * no
fna tumor sampling for cd137 modulation: a pilot study

Conditions: Head and Neck Cancer; Breast Cancer; Head and Neck Cancers; Non-Hodgkin Lymphoma; Colorectal Adenocarcinoma

Summary: the purpose of this study is to better understand the biology of the body's immune response to monoclonal antibody therapy for cancer. your health information will be used to identify your tissues. the tissue we obtain may be useful for research or education, resulting in new drugs, therapies or diagnostic procedures.


Eligibility criteria:
all patients: 1. patient must have a lymphoma, squamous cell carcinoma of the head and neck, her2+ breast adenocarcinoma, colorectal adenocarcinoma, or other solid tumor. 2. patients must not have received any immunosuppressive or anti cancer agent within 2 weeks prior to the first planned fna biopsy. 3. the patient's therapeutic plan must include a standard therapeutic monoclonal antibody (such as rituximab, cetuximab/panitumumab or trastuzumab) or an investigational monoclonal antibody) to be administered on a schedule such that a fna biopsy can be done within one week prior, and/or peripheral blood drawn immediately prior to the first dose of the therapeutic mab and immediately to 24-336 hours post dose. patients not receiving any other anti- cancer or immunosuppressive (steroids) modality within that time frame are preferred, though use of such agents does not exclude them from the study. 4. patients not receiving any immunosuppressive or anti-cancer agent within 2 weeks prior to the first planned fna biopsy are preferred. 5. informed consent must occur and be documented per institutional rules prior to the first planned fna biopsy and blood draw. patients providing an fna in addition to blood samples: criteria applicable to fna, and not required for patients providing pbmcs without fna. patients without tumors amenable to fna will be candidates for blood sampling only. if patients do not meet inclusion criteria, then they will be excluded from participating in this study. 1. patients must have a normal wbc and platelet count, must have no evidence of coagulopathy and must not have received irreversible platelet inhibitors (aspirin) for 2 weeks and reversible platelet inhibitors (other nsaids) for one week prior to the initial fna biopsy. 2. patients may not be taking therapeutic anticoagulation (target inr of \>=2) (warfarin or heparin). 3. patients must have tumor masses amenable to minimally invasive fine needle aspiration by direct visualization and/ or palpation of the tumor. generally this will be a biopsy of the primary tumor site or superficial regional lymph nodes.
dose-response study to evaluate the effect of bkr-017 on insulin resistance and other metabolic parameters in type 2 diabetes patients

Conditions: Type 2 Diabetes

Summary: this study is a randomized, double-blind, placebo-controlled, dose-response study of bkr-017 and placebo that will be conducted at two investigative sites. the total duration of subject involvement is approximately 15 weeks; the screening period can be up to 3 weeks prior to the start of test period, followed by a 12-week test period. during the test period, subjects will self-administer three tablets of test product, two times daily: before breakfast and before bedtime.


Eligibility criteria:
inclusion criteria: * males and females between the ages of 18 and 70 years at the time of screening, inclusive * diagnosed with t2d and under the care of a healthcare professional for its management, or newly diagnosed (as participant in the study) with t2d * hba1c 6.5% -10.5%, inclusive * has given written informed consent to participate in this study * willing to complete 84-day test period * willing to maintain current diet and exercise routine and current prescription medications for the duration of the study exclusion criteria: * type 1 diabetes * history of bariatric or intestinal surgery * active gastrointestinal disease including but not limited to irritable bowel syndrome, inflammatory bowel disease (e.g., crohn's disease and ulcerative colitis), diverticulitis, gastroparesis * active and clinically significant hepatic, pancreatic disease, or renal disease as determined by the investigator * history of heart disease that in the opinion of the investigator should exclude the subject from the study * severely uncontrolled hypertension at screening defined as a systolic blood pressure \> 180 mmhg or a diastolic blood pressure \> 110 mmhg on the average of two seated measurements after being at rest for at least 5 minutes * untreated or uncontrolled hyperthyroidism or hypothyroidism, or other significant thyroid disease * active significant infection as determined by the investigator * known allergy to butyrate or any of the components of the tablets * subjects planning to make major changes to diet and physical activity during the trial duration * participation in a clinical trial and/or treatment with an investigational drug during the 30 days before screening, or within 5 half-lives of receipt of an investigational drug or twice the duration of the biological effect of any investigational drug (whichever is longer) * pregnant, nursing, or trying to become pregnant * in the investigator's judgment, the subject is not suitable for the study for any other reason or cannot commit to the requirements of the study. * subject is taking one or more of the excluded therapies.